Search in:

Advanced search

OncoTargets and Therapy Volume 6, 2013 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Original Research

HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients

Tao Qin

Zhongyu Yuan

Roujun PengDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China

Bing BaiDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China

Yanxia ShiDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China

Xiaoyu TengDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China

Donggeng LiuDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China

Shusen WangDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of ChinaCorrespondence[email protected]

show all

Pages 341-347 | Published online: 09 Apr 2013

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
PubMed Web of Science ®Google Scholar
BensonJRJatoiIKeischMEstevaFJMakrisAJordanVCEarly breast cancerLancet200937396731463147919394537
PubMed Web of Science ®Google Scholar
GoldhirschAIngleJNGelberRDCoatesASThürlimannBSennHJThresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009Ann Oncol20092081319132919535820
PubMed Web of Science ®Google Scholar
PetoRDaviesCGodwinJEarly Breast Cancer Trialists’ Collaborative GroupComparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trialsLancet2012379981443244422152853
PubMed Web of Science ®Google Scholar
WolffACHammondMESchwartzJNAmerican Society of Clinical Oncology; College of American PathologistsAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerJ Clin Oncol200725111814517159189
PubMed Web of Science ®Google Scholar
RossJSSlodkowskaEASymmansWFPusztaiLRavdinPMHortobagyiGNThe HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicineOncologist200914432036819346299
PubMed Web of Science ®Google Scholar
SaxenaRDwivediAErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspectiveMed Res Rev201232116621522183797
PubMed Web of Science ®Google Scholar
HigginsMJBaselgaJTargeted therapies for breast cancerJ Clin Invest2011121103797380321965336
PubMed Web of Science ®Google Scholar
SlamonDEiermannWRobertNBreast Cancer International Research GroupAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med2011365141273128321991949
PubMed Web of Science ®Google Scholar
PerezEARomondEHSumanVJFour-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31J Clin Oncol201129253366337321768458
PubMed Web of Science ®Google Scholar
GianniLDafniUGelberRDHerceptin Adjuvant (HERA) Trial Study TeamTreatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trialLancet Oncol201112323624421354370
PubMed Web of Science ®Google Scholar
ChangHRTrastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancerCancer2010116122856286720564392
PubMed Web of Science ®Google Scholar
UntchMRezaiMLoiblSNeoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro studyJ Clin Oncol201028122024203120308670
PubMed Web of Science ®Google Scholar
GianniLEiermannWSemiglazovVNeoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortLancet2010375971237738420113825
PubMed Web of Science ®Google Scholar
CoudertBPArnouldLMoreauLPre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trialAnn Oncol200617340941416332965
PubMed Web of Science ®Google Scholar
BuzdarAUIbrahimNKFrancisDSignificantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancerJ Clin Oncol200523163676368515738535
PubMed Web of Science ®Google Scholar
KwongAMangOWWongCHChauWWLawSCHong Kong Breast Cancer Research GroupBreast cancer in Hong Kong, southern China: the first population-based analysis of epidemiological characteristics, stage-specific, cancer-specific, and disease-free survival in breast cancer patients: 1997–2001Ann Surg Oncol201118113072307821847700
PubMed Web of Science ®Google Scholar
WangYYinQYuQA retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatmentsBreast Cancer Res Treat2011130248949821837481
PubMed Web of Science ®Google Scholar
ZhengSBaiJQLiJThe pathologic characteristics of breast cancer in China and its shift during 1999–2008: a national-wide multicenter cross-sectional image over 10 yearsInt J Cancer2012131112622263122377956
PubMed Web of Science ®Google Scholar
ChenWJiangZShaoZSunQShenKAn economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancerValue Health200912 Suppl 3S82S8420586989
PubMed Web of Science ®Google Scholar
DawoodSBroglioKBuzdarAUHortobagyiGNGiordanoSHPrognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based reviewJ Clin Oncol2010281929819933921
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date